Key result
Lactoferricin B-derived peptides lower blood pressure in spontaneously hypertensive rats.
Answers are grounded in this paper and cite their sources.
A set of eight lactoferricin B (LfcinB)-derived peptides was examined for inhibitory effects on angiotensin I-converting enzyme (ACE) activity and ACE-dependent vasoconstriction, and their hypotensive effect in spontaneously hypertensive rats (SHR). Peptides were derived from different elongations both at the C-terminal and N-terminal ends of the representative peptide LfcinB(20-25), which is known as the LfcinB antimicrobial core. All of the eight LfcinB-derived peptides showed in vitro inhibitory effects on ACE activity with different IC(50) values. Moreover, seven of them showed ex vivo inhibitory effects on ACE-dependent vasoconstriction. No clear correlation between in vitro and ex vivo inhibitory effects was found. Only LfcinB(20-25) and one of its fragments, F1, generated after a simulated gastrointestinal digestion, showed significant antihypertensive effects in SHR after oral administration. Remarkably, F1 did not show any effect on ACE-dependent vasoconstriction in contrast to the inhibitory effect showed by LfcinB(20-25). In conclusion, two LfcinB-derived peptides lower blood pressure and exhibit potential as orally effective antihypertensive compounds, yet a complete elucidation of the mechanism(s) involved deserves further ongoing research.
No takes yet. Share an insight, caveat, or question.
Ruiz-Giménez et al. (2010) studied Hypertension (in spontaneously hypertensive rats). Lactoferricin B (LfcinB)-derived peptides (LfcinB(20-25) and fragment F1) was evaluated on Inhibitory effects on ACE activity, ACE-dependent vasoconstriction, and hypotensive effect. Oral administration of lactoferricin B-derived peptide LfcinB(20-25) and its fragment F1 demonstrated significant antihypertensive effects in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: